Prognostic Significance of B-Lineage Leukemic Cell Growth in SCID Mice: A Children's Cancer Group Study

References

• Pui C.H., Behm F.G., Singh B., et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75: 174–179
   PubMed Web of Science ®Google Scholar
• Pui C.H., Behm F.G., Crist W.M. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343–362
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Gajl Peczalska K.J., Provisor A.J., et al. Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 1989; 73: 271–280
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Ledbetter J.A. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci USA 1988; 85: 8603–8607
   PubMed Web of Science ®Google Scholar
• Smith M., Arthur D., Camitta B., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia [see comments]. J Clin Oncol 1996; 14: 18–24
   PubMed Web of Science ®Google Scholar
• Uckun F., Reaman G., Steinherz P., et al. Improved Outcome for Children with T-Lineage Acute Lymphoblastic Leukemia After Contemporary Chemotherapy: A Children's Cancer Group Study. Leuk & Lymphoma 1996; 24: 57–70
   PubMed Web of Science ®Google Scholar
• Uckun F.M. Severe combined immunodeficient mouse models of human leukemia. Blood 1996; 88: 1135–1146
   PubMed Web of Science ®Google Scholar
• Cesano A., O'Connor R., Lange B., et al. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 1991; 77: 2463–2474
   PubMed Web of Science ®Google Scholar
• Dick J.E., Lapidot T., Pflumio F. Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis. Immunol Rev 1991; 124: 25–43
   PubMed Web of Science ®Google Scholar
• Kamel Reid S., Letarte M., Sirard C., et al. A model of human acute lymphoblastic leukemia in immune-deficient scid mice. Science 1989; 246: 1597–1600
   PubMed Web of Science ®Google Scholar
• Kamel Reid S., Letarte M., Doedens M., et al. Bone marrow from children in relapse with pre-B acute lym-phoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood 1991; 78: 2973–2981
   PubMed Web of Science ®Google Scholar
• McCune J.M., Namikawa R., Kaneshima H., et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632–1639
   PubMed Web of Science ®Google Scholar
• Mosier D.E., Gulizia R.J., Baird S.M., et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256–259
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Chelstrom L.M., Finnegan D., et al. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD 19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116–3129
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Manivel C., Arthur D., et al. In vivo efficacy of B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201–2214
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Downing J.R., Chelstrom L.M., et al. Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1994; 84: 859–865
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Downing J.R., Gunther R., et al. Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1993; 81: 3052–3062
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Sather H., Reaman G., et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 1995; 85: 873–878
   PubMed Web of Science ®Google Scholar
• Steinherz P.G., Siegel S.E., Bleyer W.A., et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 1991; 68: 751–758
   PubMed Web of Science ®Google Scholar
• Gunther R., Chelstrom L.M., Finnegan D., et al. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993; 7: 298–309
   PubMed Web of Science ®Google Scholar
• Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Peto R., Pike M.C, Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Pullen D.J., Boyett J.M., Crist W.M., et al. Pediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. Ann N Y Acad Sci 1984; 428: 26–48
   PubMed Web of Science ®Google Scholar
• Gajjar A., Ribeiro R., Hancock M.L., et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292–1295
   PubMed Web of Science ®Google Scholar
• Gaynon P.S., Bleyer W.A., Steinherz P.G., et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273–279
   PubMedGoogle Scholar
• Riehm H., Reiter A., Schrappe M., et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987; 199: 151–160
   PubMed Web of Science ®Google Scholar
• Reiter A., Schrappe M., Ludwig W.D., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multi-center trial ALL-BFM 86. Blood 1994; 84: 3122–3133
   PubMed Web of Science ®Google Scholar
• Schrappe M., Reiter A., Sauter S., et al. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. Klin Padiatr 1994; 206: 208–221
   PubMed Web of Science ®Google Scholar
• Steinherz P.G., Gaynon P.S., Breneman J.C., et al. Cytoreduction and prognosis in acute lymphoblastic leukemia—the importance of early marrow response: report from the Childrens Cancer Group. J. Clin Oncol 1996; 14: 389–398
   PubMed Web of Science ®Google Scholar
• Steinherz P.G., Gaynon P., Miller D.R., et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen—a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol 1986; 4: 744–752
   PubMed Web of Science ®Google Scholar
• Nachman J., Sather H.N., Gaynon P.S., et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 2222–2230
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Stewart C.F., Reaman G., et al. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 1995; 85: 2817–2828
   PubMed Web of Science ®Google Scholar
• Waurzyniak B., Schneider E.A., Turner N., et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (Anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 1997; 3: 881–890
   PubMed Web of Science ®Google Scholar
• Waddick K.G., Myers D.E., Gunther R., et al. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood 1995; 86: 4228–4233
   PubMed Web of Science ®Google Scholar